Cannabidiol-Induced Acute Generalized Exanthematous Pustulosis

Pettit, Cory; Massick, Susan; Bechtel, Mark

doi:10.1097/der.0000000000000422

Cited by 13 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case Reports in Ophthalmological Medicine exanthematous pustulosis (AGEP) in the setting of CBD use which is a type IV hypersensitivity similar to SJS-TEN [11]. In our case, the patient has previously utilized other commer-cial CBD products without side effects or associated allergic reactions.…”

mentioning

confidence: 93%

Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome

Yin

Hadjokas

Mirchia

et al. 2020

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

Purpose. To report an unusual presentation of commercial cannabidiol (CBD) oil-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS-TEN). Methods. A 56-year-old woman presented with acute onset of a diffuse, blistering, maculopapular rash with over 30% total body surface area (BSA) involvement two days after taking CBD oil sublingually for chronic pain. Biopsy confirmed SJS-TEN. Ophthalmology was consulted and mild eye involvement was found. She was started on topical cyclosporine, prednisone, moxifloxacin, and erythromycin ointment to prevent progression, which was successful. She was otherwise treated with supportive therapy in the intensive care burn unit and ultimately passed away from septic shock. Conclusion. In this case, we described an unusual drug-induced SJS from a commercial, non-FDA-regulated cannabis product. The use of a commercial CBD product should be cautioned due to potential for series of drug reactions to the cannabis product and the risk for reaction to other unregulated other pharmacological components.

show abstract

mentioning

confidence: 93%

Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome

Yin

Hadjokas

Mirchia

et al. 2020

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

show abstract

“…6,7 A CADR described as acute generalized exanthematous pustulosis occurred on the limbs, groin and buttocks of a man, 48 h after CBD oil ingestion. 8 Erythema multiforme (EM)-like cutaneous drug eruptions were described in a person after each repeated exposure to cannabis. 9 Most recently, SJS was reported in a woman two days after receiving sublingual CBD oil.…”

Section: Discussionmentioning

confidence: 99%

Probable cutaneous adverse drug reaction due to a cannabidiol‐containing hemp oil product in a dog

Simpson

Bradley

Schissler

2020

Veterinary Dermatology

View full text Add to dashboard Cite

Background Cannabidiol (CBD) in hemp oil has become a widely used product in veterinary medicine. To date, there have been no reports of cutaneous adverse events associated with CBD‐containing oil in the veterinary literature. Clinical summary A 4‐year‐old castrated male Labrador retriever presented with pad sloughing and rapidly progressive cutaneous and mucosal ulceration within five days of administering an oral CBD oil product. Histopathological findings in combination with cutaneous signs were consistent with Stevens–Johnson syndrome. All lesions completely resolved after discontinuation of the hemp oil in addition to a 12 day course of cephalexin and prednisone. Given the lack of alternative causes including other medications, an adverse drug event was deemed probable according to the Naranjo algorithm. Conclusions and clinical importance To the best of the authors’ knowledge, this is the first report of suspected cutaneous adverse drug reaction to a CBD‐containing hemp oil product.

show abstract

“…The subjects received isolated oral CBD (99.6% purity with no other cannabinoid; PurMed Global; United States) dissolved in medium-chain triglyceride oil (150 mg/ml) at a daily dose of 300 mg (150 mg twice per day) for 4 weeks. To the best of our knowledge, these are the first case reports with multiple individuals not using other medications, with an extensive investigation to exclude other clinical causes ( Pettit et al, 2018 ; Singh and Antimisiaris, 2020 ). Half of the patients were exposed only to the vehicle (medium-chain triglyceride (MCT) oil) to confirm that the adverse effect was specifically related to CBD use.…”

Section: Introductionmentioning

confidence: 94%

Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations

et al. 2022

View full text Add to dashboard Cite

Cannabidiol (CBD) is a non-psychotomimetic constituent of the Cannabis plant, with potential therapeutic properties for many physical and neuropsychiatric conditions. Isolated CBD has been suggested to have favorable safety and tolerability. Although CBD-related rash is described, few case reports are well documented in the literature, and usually, CBD was used concomitantly with other medications. Thus, we report four women who presented a skin rash after ongoing CBD use. Other causes of these skin rashes were ruled out after conducting an extensive viral and serological detection panel, and three patients had their lesions biopsied. Two patients were re-exposed to the vehicle (MCT) without developing a new skin rash. Therefore, clinicians must be aware of this potential adverse effect of CBD use.

show abstract

Cannabidiol-Induced Acute Generalized Exanthematous Pustulosis

Cited by 13 publications

References 3 publications

Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome

Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome

Probable cutaneous adverse drug reaction due to a cannabidiol‐containing hemp oil product in a dog

Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations

Contact Info

Product

Resources

About